Amgen Inc. has announced positive topline results from the Phase 3 FORTITUDE-101 clinical trial, which evaluated the efficacy of bemarituzumab plus chemotherapy in patients with FGFR2b overexpression in first-line gastric cancer. The trial met its primary endpoint, showing a significant improvement in overall survival compared to chemotherapy alone. The most common adverse events in this treatment group included reduced visual acuity, punctate keratitis, and anemia among others. Detailed results from the study are set to be presented at a future medical meeting. Additionally, a Phase 3 study involving bemarituzumab, chemotherapy, and nivolumab is currently ongoing, with results expected in the second half of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA20853) on June 30, 2025, and is solely responsible for the information contained therein.